Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3Active not recruiting 3Recruiting 2

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 32Lymphoma, Follicular 25Lymphoma, Mantle-Cell 23Lymphoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Lymphoma, Non-Hodgkin 21Lymphoma, B-Cell 16Lymphoma, B-Cell, Marginal Zone 13Neoplasms 8Recurrence 7Waldenstrom Macroglobulinemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia 5Burkitt Lymphoma 5Neoplasm, Residual 3Lymphoproliferative Disorders 3Leukemia, Hairy Cell 3Hematologic Diseases 3Myelodysplastic Syndromes 2Lymphoma, AIDS-Related 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Biphenotypic, Acute 2Blast Crisis 2Sarcoma, Myeloid 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neuritis 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myeloid Diseases 1

Interventions

fludarabine phosphate 4Cyclophosphamide 4blinatumomab 3Rituximab 3Lenalidomide 2Immunotherapy, Adoptive 2venetoclax 1trastuzumab deruxtecan 1tisagenlecleucel 1pembrolizumab 1obinutuzumab 1niraparib 1nilotinib 1isatuximab 1acalabrutinib 1Zymosan 1Whole-Body Irradiation 1Trastuzumab 1Sodium Chloride 1Sirolimus 1Radiotherapy 1Pentostatin 1NKTR-255 1Mycophenolic Acid 1Melphalan 1Magnetic Resonance Imaging 1Immunotherapy 1Imatinib Mesylate 1Histamine Antagonists 1Exercise Test 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasm, Residual × Rituximab × Clear all
NCT03863184 2026-04-28

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Weill Medical College of Cornell University

Phase 2 Active not recruiting
37 enrolled 9 charts
Lymphoid

Neoplasm, Residual, Lymphoma, Mantle-Cell

NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡